Plauth M, Raible A, Graser T A, Nöldeke I L, Fürst P, Dölle W, Hartmann F
Medizinische Klinik und Poliklinik, Abteilung Innere Medizin, Eberhard-Karls-Universität Tübingen.
Z Gastroenterol. 1994 Mar;32(3):141-5.
It has been hypothesized that the beneficial effect on hepatic encephalopathy of lactulose or neomycin might be exerted by their effect on intermediary glutamine metabolism and ammonia generation within enterocytes. We examined glutamine consumption and the production of alanine and ammonia (net substrate exchange in nmol min-1 g-1) in isolated vascularly and luminally perfused small intestine from rats with and without pretreatment with lactulose (2.0 g/kg) or paromomycin (60 mg/kg). Without pretreatment, 50 mM lactulose or 1 mM paromomycin were equally ineffective to significantly reduce the consumption of arterial glutamine (-92 +/- 5 vs. -80 +/- 6 vs. -71 +/- 6 for controls, lactulose, or paromomycin; mean +/- SEM, n = 6 each, n.s. by analysis of variance), and the production of alanine (41 +/- 3 vs. 44 +/- 3 vs. 61 +/- 7, n.s.) or ammonia (42 +/- 6 vs. 42 +/- 6 vs. 38 +/- 6, n.s.). Similarly, glutamine utilisation, and the release of alanine and ammonia were not different after pretreatment for 10 days. Also, both agents did not reduce glutamine absorption from the lumen (-170 +/- 9 vs. -171 +/- 6 vs. -219 +/- 25, n = 5 each) or the concomitant vascular release of metabolic products alanine (92 +/- 7 vs. 78 +/- 10 vs. 77 +/- 10 vs. 77 +/- 7, n.s.) and ammonia (73 +/- 6 vs. 69 +/- 7 vs. 65 +/- 8, n.s.). Our results do not support the hypothesis, that lactulose or paromomycin reduce ammonia generation by small intestinal mucosa through a specific effect on intermediary glutamine metabolism.
有人提出假说,乳果糖或新霉素对肝性脑病的有益作用可能是通过它们对肠细胞内谷氨酰胺中间代谢和氨生成的影响来实现的。我们检测了在有或没有用乳果糖(2.0 g/kg)或巴龙霉素(60 mg/kg)预处理的大鼠中,分离的经血管和管腔灌注的小肠中谷氨酰胺的消耗以及丙氨酸和氨的生成(以nmol min-1 g-1为单位的净底物交换)。未经预处理时,50 mM乳果糖或1 mM巴龙霉素均不能有效显著降低动脉谷氨酰胺的消耗(对照组、乳果糖组或巴龙霉素组分别为-92±5 vs. -80±6 vs. -71±6;均值±标准误,每组n = 6,方差分析无显著性差异),以及丙氨酸的生成(41±3 vs. 44±3 vs. 61±7,无显著性差异)或氨的生成(42±6 vs. 42±6 vs. 38±6,无显著性差异)。同样,预处理10天后,谷氨酰胺的利用以及丙氨酸和氨的释放也没有差异。此外,两种药物均未降低从肠腔吸收的谷氨酰胺(每组n = 5,分别为-170±9 vs. -171±6 vs. -219±25)或代谢产物丙氨酸(92±7 vs. 78±10 vs. 77±10 vs. 77±7,无显著性差异)和氨(73±6 vs. 69±7 vs. 65±8,无显著性差异)的伴随性血管释放。我们的结果不支持乳果糖或巴龙霉素通过对谷氨酰胺中间代谢的特定作用来减少小肠黏膜氨生成的假说。